QNTM

Quantum BioPharma Ltd. (QNTM) Business Model Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-09-01

Overall Score

Revenue Model

No meaningful revenue base is reflected in the TTM metrics, with revenue per share at 0 and price-to-sales at 0.

The business appears to be operating without a demonstrated monetization profile in the current trailing data.

Profitability

TTM margins are effectively 0 across gross, operating, EBITDA, pretax, and net profit, indicating no current profitability.

Returns remain deeply negative, including ROA of -1.73, ROE of -4.13, and ROIC of -0.27.

Cash Generation

Operating cash flow and free cash flow are both negative, with OCF per share at -0.81 and FCF per share at -0.81.

Cash flow coverage remains weak, with operating cash flow ratio at -0.65 and free cash flow yield at -0.27.

Balance Sheet Strength

Liquidity is acceptable with a current ratio of 1.20 and quick ratio of 1.19.

Leverage is modest, with debt-to-equity at 0.12 and debt-to-assets at 0.07, though solvency and interest coverage are weak.

Scalability Operating Leverage

There is no evidence of operating leverage in the trailing data because operating margins remain at 0.

The business is not yet showing scale benefits through higher returns or positive cash conversion.

Moat Pricing Power

Zero gross and operating margins suggest limited pricing power in the current period.

The company does not yet demonstrate durable economic advantages through returns or margin structure.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Quantum BioPharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →